Company intelligence / Profile preview

Tairong

Hangzhou, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

Tairong Pharmaceutical is a pharmaceutical company based in China, operating as a key subsidiary of Zhejiang Huahai Pharmaceutical. The company focuses on the research, development, and manufacturing of innovative small molecule drugs and high-end generic formulations. Its pipeline includes candidates targeting metabolic diseases, cardiovascular conditions, and central nervous system disorders, with its lead program, TR-001, currently in clinical development for hyperuricemia and gout. Tairong leverages the extensive manufacturing and global supply chain capabilities of its parent company to bring novel therapies to market.

Therapeutic areas: RheumatologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Partnerships

Zhejiang Huahai Pharmaceutical

Beyond the preview

Go deeper on Tairong.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tairong.

Explore the full profile